As of March 23, 2026, Kyverna Therapeutics's top three insider holders are Capital Life Sciences Investors, Llc Bain (TenPercentOwner, 3.16Mn shares), Biopartners Opportunity Fund I, L.P. Westlake (TenPercentOwner, 869.32K shares), Beth C Seidenberg (Director, 869.32K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Sciences, Inc. Gilead | 4,126,119 | 0 | 13 Feb, 2024 | |
| Capital Life Sciences Investors, Llc Bain | 0 | 3,163,868 | 14 Feb, 2024 | |
| Biopartners Opportunity Fund I, L.P. Westlake | 0 | 869,317 | 22 Dec, 2025 | |
| Beth C Seidenberg | 0 | 869,317 | 22 Dec, 2025 | |
| Ventures Iii Gp, Llc Northpond | 0 | 450,000 | 12 Feb, 2024 | |
| Christi Shaw | Executive Chairperson | 70,935 | 0 | 14 Jan, 2026 |
| Warner Weston Biddle | Chief Executive Officer | 58,000 | 0 | 17 Mar, 2026 |
| Ryan Alexander Jones | Chief Financial Officer | 55,950 | 0 | 15 Apr, 2025 |
| Karen Marie Walker | Chief Technology Officer | 22,636 | 0 | 17 Dec, 2025 |
| Naji Gehchan | See Remarks | 18,000 | 0 | 17 Mar, 2026 |
| Mert Aktar | 16,634 | 0 | 02 Jun, 2025 | |
| Daniel K Spiegelman | 16,634 | 0 | 02 Jun, 2025 | |
| Beth C Seidenberg | 16,634 | 0 | 02 Jun, 2025 | |
| Andrew Craig Miller | 11,006 | 0 | 04 Mar, 2026 | |
| Sravan Kumar Emany | 11,006 | 0 | 26 Feb, 2026 | |
| Marc Grasso | Chief Financial Officer | 10,000 | 0 | 17 Mar, 2026 |
| Ventures, Llc Vida | 0 | 583 | 14 Feb, 2024 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 13 Mar, 2026 | Warner Weston Biddle | Common Stock | A | 58,000 | $0.00 | 58,000 | D | A |
| 13 Mar, 2026 | Marc Grasso | Common Stock | A | 10,000 | $0.00 | 10,000 | D | A |
| 13 Mar, 2026 | Naji Gehchan | Common Stock | A | 18,000 | $0.00 | 18,000 | D | A |
| 13 Mar, 2026 | Naji Gehchan | Stock Option (right to buy) | A | 105,000 | $0.00 | 105,000 | D | A |
| 13 Mar, 2026 | Warner Weston Biddle | Stock Option (right to buy) | A | 350,000 | $0.00 | 350,000 | D | A |
| 13 Mar, 2026 | Marc Grasso | Stock Option (right to buy) | A | 65,000 | $0.00 | 65,000 | D | A |
| 24 Feb, 2026 | Andrew Craig Miller | Common Stock | A | 11,006 | $0.00 | 11,006 | D | A |
| 24 Feb, 2026 | Andrew Craig Miller | Stock Option (right to buy) | A | 42,945 | $0.00 | 42,945 | D | A |
| 24 Feb, 2026 | Sravan Kumar Emany | Common Stock | A | 11,006 | $0.00 | 11,006 | D | A |
| 24 Feb, 2026 | Sravan Kumar Emany | Stock Option (right to buy) | A | 42,945 | $0.00 | 42,945 | D | A |
| 09 Feb, 2026 | Mayobanex Pujols | Stock Option (right to buy) | A | 300,000 | $0.00 | 300,000 | D | A |
| 12 Jan, 2026 | Christi Shaw | Common Stock | A | 30,000 | $0.00 | 46,634 | D | A |
| 12 Jan, 2026 | Christi Shaw | Common Stock | A | 24,301 | $0.00 | 70,935 | D | A |
| 12 Jan, 2026 | Christi Shaw | Stock Option (right to buy) | A | 185,000 | $0.00 | 185,000 | D | A |
| 18 Dec, 2025 | Biopartners Opportunity Fund I, L.P. Westlake | Common Stock | A | 133,333 | $7.50 | 869,317 | I | P |
| 18 Dec, 2025 | Beth C Seidenberg | Common Stock | A | 133,333 | $7.50 | 869,317 | I | P |
| 15 Dec, 2025 | Karen Marie Walker | Common Stock | A | 23,998 | $4.83 | 46,634 | D | M |
| 15 Dec, 2025 | Karen Marie Walker | Common Stock | D | 23,998 | $12.20 | 22,636 | D | S |
| 15 Dec, 2025 | Karen Marie Walker | Stock option (right to buy) | D | 23,998 | $0.00 | 85,865 | D | M |
| 30 Jun, 2025 | Marc Grasso | Stock Option (right to buy) | D | 450,000 | $0.00 | 450,000 | D | A |